Op-Eds
Scapegoating Patents Won’t Lower Drug Prices
In their quest to lower drug prices, some US leaders have identified a convenient scapegoat: patents.
The Law is Clear: There’s No Legal Authority to Control Prices Via Bayh-Dole
On the question of taking action to lower prescription drug prices, progressive lawmakers are of two minds. Some argue that Congress should simply pass legislation to allow the government to set the price for prescription medications. That approach, whether wise on policy grounds or not, at least has the virtue of fidelity to our constitutional process of lawmaking.
Removing patent rights to lower drug costs is dangerous precedent
Walter G. Copan Opinion: Removing patent rights to lower drug costs is dangerous precedent The Denver Post
China’s formidable technology challenge
Paul R. Michel https://www.washingtontimes.com/news/2022/mar/16/chinas-formidable-technology-challenge/ The International Business Times
U.S. patent system weakens: Protect IP to keep American tech at the top
Paul R. Michel U.S. patent system weakens: Protect IP to keep American tech at the top VentureBeat
The U.S. must fix its innovation engine: the patent system
Adam Mossoff The U.S. must fix its innovation engine: the patent system STAT
US Economy 2022: Diversity And Inclusion For The Heartland
Paul R. Michel https://www.ibtimes.com/us-economy-2022-diversity-inclusion-heartland-3425396 The International Business Times
Lawmakers want to weaken U.S. patents that made new anti-COVID pills possible. We should do everything to protect them
Andrei Iancu, David Kappos, and Paul R. Michel https://fortune.com/2022/03/04/new-covid-pills-patents-pfizer-merk-ip-pandemic-pharma-health-iancu-kappos-michel/ Fortune
Big Tech is abusing the U.S. patent challenge system
Paul R. Michel https://news.trust.org/item/20220218102516-a1p08 Reuters